Daratumumab for late antibody-mediated rejection in kidney transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received a kidney transplant (first or later one)
- You were diagnosed with antibody-mediated rejection more than 12 months after your transplant
- A biopsy has confirmed this type of rejection
- You have new donor-specific antibodies (DSA)
- You do not have an active infection or serious health issues that could interfere
- You have not been treated with daratumumab before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This Phase 2 trial tests daratumumab to reduce your body’s immune reaction (HLA antibodies) before a heart or heart-and-kidney transplant. It may help lower the risk of immediate, severe rejection in people who already have high antibody levels.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This study tests a new medicine called mezagitamab for people whose kidney transplant is being rejected by their immune system more than 6 months after transplant. The drug may help prevent further kidney damage and preserve your transplant.
This trial tests if daratumumab, a targeted antibody therapy, can help patients with aplastic anemia that hasn't improved after standard treatments. It's for adults who cannot or choose not to have a stem cell transplant.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Hear when a new Kidney Tansplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.